OncoMatch/Clinical Trials/NCT03708224
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
Is NCT03708224 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Atezolizumab and Tocilizumab for cancer.
Treatment: Atezolizumab · Tocilizumab · Tiragolumab — To determine the effect of neoadjuvant atezolizumab alone or in combination with other immune modulating agents on T-cell infiltration in advanced SCCHN. To determine the impact of neo-adjuvant immunotherapy on surgical outcomes.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-cancer monoclonal antibody
prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1
Cannot have received: targeted small molecule therapy
prior targeted small molecule therapy within 2 weeks prior to study day 1
Cannot have received: radiation therapy
radiation therapy within 2 weeks prior to study day 1
Cannot have received: anti-CTLA4 therapy
prior therapy with an anti-CTLA4 agent
Cannot have received: anti-PD-1 therapy
prior therapy with an anti-PD-1 agent
Cannot have received: anti-PD-L1 therapy
prior therapy with an anti-PD-L1 agent
Cannot have received: anti-PD-L2 therapy
prior therapy with an anti-PD-L2 agent
Cannot have received: cell-depleting therapies (CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19, anti-CD20)
Previous treatment with any cell-depleting therapies, including investigational agents or approved therapies, some examples include: CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-Cluster of Differentiation 19 (CD19) and anti-CD20
Cannot have received: alkylating agent (chlorambucil)
Any previous treatment with alkylating agents such as chlorambucil
Cannot have received: total lymphoid irradiation
any previous treatment with total lymphoid irradiation
Cannot have received: tocilizumab (tocilizumab)
Exception: exception may be granted for upon application to the sponsor on a case-by-case basis
Previous treatment with tocilizumab (an exception to this criterion may be granted for upon application to the sponsor on a case-by-case basis)
Lab requirements
Blood counts
ANC >=1,500 /mcL; Platelets >=100,000 /mcL; Hemoglobin >= 9 g/dL; Lymphocyte count >= 500/mcL; White blood count >=3,000/mcL or <=14,000/mcL
Kidney function
Serum creatinine <= 1.5 x ULN OR ≥50 mL/min creatinine clearance by Cockcroft-Gault formula
Liver function
Serum total bilirubin <= 1.5 x ULN OR direct bilirubin <= ULN for subjects with total bilirubin levels > 1.5 ULN (excluding Gilbert's syndrome); AST and ALT <= 3 x ULN; Albumin >= 2.5 mg/dL
Demonstrate adequate organ function as defined below. ... (see full criteria for details)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of San Francisco, California · San Francisco, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03708224 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-cancer monoclonal antibody, targeted small molecule therapy, radiation therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages